arrow
M

Muzaffar H. Qazilbash

The University of Texas MD Anderson Cancer Center
H指数:52
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Daratumumab ± pomalidomide maintenance after salvage autologous transplantation in relapsed multiple myeloma: a phase 2 study

在复发多发性骨髓瘤中,自体移植后使用达鲁单抗±泊马利度胺进行维持治疗:一项2期研究

2026-09-260
OAAI
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma

卡非佐米、来那度胺和地塞米松(KRd)与硼替佐米、来那度胺和地塞米松(VRd)在自体造血干细胞移植/移植前诱导治疗新诊断多发性骨髓瘤的比较

2026-08-200
PRE
Donor-specific HLA mismatch: haploidentical versus 7/8 mismatched unrelated donor hematopoietic cell transplantation with PTCy

供者特异性HLA错配:单倍型与7/8位点错配无关供者造血干细胞移植联合PTCy

2026-06-170
PRE
D-VRD induction and autologous transplant in patients ≥70 years

D-VRD诱导和自体移植在≥70岁患者中的应用

2026-06-050
OAAI
Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma

遗传血统与复发/难治性多发性骨髓瘤患者接受伊decabtagene vicleucel治疗后结局和毒性的关联

2026-04-130
OAAI
Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review

多发性骨髓瘤移植不合格定义不一致: 一项系统评价

2026-01-010
OAAI
Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myeloma

延迟或挽救性自体造血干细胞移植治疗多发性骨髓瘤的结果

2025-12-050
PRE
Author Correction: Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation

作者更正:造血干细胞自体移植后的克隆性进化

2025-08-110
OAAI
Outcomes of Patients with Multiple Myeloma with deletion 1p Following Autologous Stem Cell Transplant

多发性骨髓瘤患者伴有1p缺失行自体干细胞移植后的结局

2025-08-050
PRE
Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial

作者更正: 同种异体NK细胞与双特异性先天细胞衔接器治疗难治性复发性淋巴瘤: 1期试验

2025-06-260
PRE
Outcomes of Multiple Myeloma Patients With Prior Solid Tumors Undergoing Autologous Transplantation

多发性骨髓瘤患者既往有实体瘤病史行自体移植的结局

2025-05-160
PRE
The Impact of Melphalan Conditioning and CD34+ Cell Dose and Schedule on Post-Transplant Outcomes in AL Amyloidosis

美法仑预处理、CD34+细胞剂量及输注方案对AL型淀粉样变性移植后结局的影响

2025-04-110
PRE
Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17p
2025-01-010
PRE
Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis

年龄对AL淀粉样变性自体干细胞移植结局的影响

BLOOD
IF23.1
2024-11-050
PRE
Impact of Donor Age and Donor-Recipient Sex Mismatch on HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation Outcomes

供者年龄和供-受者性别不匹配对HLA匹配的亲属与非亲属供者造血细胞移植结局的影响

BLOOD
IF23.1
2024-11-050
PRE
Improved Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation with Younger Donors

供者年龄较轻的半相合造血干细胞移植疗效改善

BLOOD
IF23.1
2024-11-050
PRE
Second Line Treatment in Patients with Multiple Myeloma Progressing after Bortezomib, Lenalidomide, Dexamethasone Induction, Autologous Transplant and Lenalidomide Maintenance

二线治疗在经硼替佐米、来那度胺、地塞米松诱导,自体移植和来那度胺维持治疗后进展的多发性骨髓瘤患者中的应用

BLOOD
IF23.1
2024-11-050
PRE